<p>Organon &amp; Co. (NYSE:OGN - 獲取免費報告) 的股價在週五達到了新的 52 周低點。該股最低交易價為$13.25，最後交易價為$13.18，成交量為 785212 股。該股之前的收盤價為$14.45。</p>
<p>獲取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>道瓊斯最熱門的股票默克準備發佈第四季度財報</li>
</ul>
<p>幾位研究分析師最近對該公司發佈了報告。摩根士丹利在 2 月 14 日的研究報告中將 Organon &amp; Co.的目標價從$17.00 下調至$16.00，並給予該公司 “持平” 評級。TD Cowen 在 1 月 15 日的研究報告中將 Organon &amp; Co.的股票評級上調至 “持有”。最後，巴克萊在 2 月 14 日的研究報告中將 Organon &amp; Co.的目標價從$26.00 下調至$24.00，並給予該公司 “增持” 評級。一位分析師對該股給予了賣出評級，三位分析師給予了持有評級，兩位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat.com 的數據，該股目前的平均評級為 “持有”，平均目標價為$20.80。</p>
<p><strong>閲讀我們最新的 Organon &amp; Co.股票報告</strong></p>
<h2>Organon &amp; Co. 股價下跌 9.6%</h2>
<ul>
<li>Lululemon Athletica 因進入標準普爾 500 指數而創下新高</li>
</ul>
<p>該公司的 50 日簡單移動平均線為$15.22，200 日簡單移動平均線為$16.10。該公司的市值為 33.7 億美元，市盈率為 3.92，市盈增長比率為 0.90，貝塔值為 0.76。該公司的速動比率為 1.21，流動比率為 1.70，債務股本比率為 17.73。</p>
<p>Organon &amp; Co. (NYSE:OGN - 獲取免費報告) 最近在 2 月 13 日發佈了季度財報。該公司報告每股收益（EPS）為$0.83，低於市場共識預期的$0.92，差額為 ($0.09)。Organon &amp; Co.的股本回報率為 431.62%，淨利潤率為 13.49%。該公司本季度的收入為 15.9 億美元，而市場共識預期為 15.7 億美元。股票分析師預計 Organon &amp; Co.在當前年度的每股收益將達到 3.68。</p>
<h2>Organon &amp; Co. 分紅公告</h2>
<p>該公司最近宣佈了季度分紅，已於 3 月 13 日支付。2 月 24 日的登記投資者獲得了$0.28 的分紅。該分紅的除息日期為 2 月 24 日。這代表着年化分紅為$1.12，分紅收益率為 8.57%。Organon &amp; Co.的派息比率目前為 33.63%。</p>
<h2>Organon &amp; Co. 的機構交易</h2>
<p>機構投資者最近對該股票的持倉進行了調整。Quantbot Technologies LP 在第三季度購買了 Organon &amp; Co.的新股份，價值約為$113,000。蘇黎世州立銀行在第三季度將其在 Organon &amp; Co.的持倉提高了 8.4%。蘇黎世州立銀行現在擁有該公司 55,506 股股票，價值$1,062,000，此前在該期間又購買了 4,298 股。瑞銀資產管理美國有限公司的一個獨立業務單位在第三季度將其在 Organon &amp; Co.的持倉提高了 0.5%。瑞銀資產管理美國有限公司的一個獨立業務單位現在擁有 836,389 股該公司的股票，價值$16,000,000，此前在上個季度又購買了 4,029 股。Verition Fund Management LLC 在第三季度購買了 Organon &amp; Co.的新股份，價值$195,000。最後，Paloma Partners Management Co 在第三季度購買了 Organon &amp; Co.的股份，價值約為$362,000。對沖基金和其他機構投資者持有該公司 77.43% 的股票。</p>
<h2>Organon &amp; Co. 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Organon &amp; Co.是一家基於科學的全球製藥公司，致力於通過一系列處方療法在女性健康、生物類似藥和成熟品牌領域開發和提供創新健康解決方案。該公司成立於 2020 年 3 月 11 日，總部位於新澤西州澤西市。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Organon &amp; Co.更好</li>
<li>內部人士買入解釋：投資者需要知道的事項</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>投資便士股票需要知道的事項</li>
<li>空頭賣家對這三隻半導體股票是否錯誤？</li>
<li>投資建築股票</li>
<li>波音在 3 月份獲得 500 億美元訂單——BA 股票現在值得買嗎？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Organon &amp; Co.嗎？</h2>
<p>在考慮投資 Organon &amp; Co.之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Organon &amp; Co.並不在名單上。</p>
<p>雖然 Organon &amp; Co.目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Organon & Co.（紐約證券交易所代碼：OGN）達到了新的 52 周低點 13.18 美元，較之前的收盤價 14.45 美元下跌。分析師的評級意見不一，摩根士丹利將其目標價下調至 16.00 美元，巴克萊則將目標價降低至 24.00 美元。該股票的平均評級為 “持有”，目標價為 20.80 美元。公司報告第四季度每股收益為 0.83 美元，未達到預期，並宣佈季度股息為 0.28 美元。機構投資者持有該股票的 77.43%，顯示出儘管近期價格下跌，仍然有強烈的投資興趣</p>

<p>Organon &amp; Co. (NYSE:OGN - Get Free Report)'s stock price reached a new 52-week low on Friday . The stock traded as low as $13.25 and last traded at $13.18, with a volume of 785212 shares. The stock had previously closed at $14.45.</p>
<div class="lb-trans"><p>Organon &amp; Co. (NYSE:OGN - 獲取免費報告) 的股價在週五達到了新的 52 周低點。該股最低交易價為$13.25，最後交易價為$13.18，成交量為 785212 股。該股之前的收盤價為$14.45。</p>
</div><p>Get <strong>Organon &amp; Co.</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Merck, the Dow's hottest stock, gets set to report Q4 financials</li>
</ul>
<div class="lb-trans"><ul>
<li>道瓊斯最熱門的股票默克準備發佈第四季度財報</li>
</ul>
</div><p>Several research analysts recently issued reports on the company. Morgan Stanley lowered their target price on Organon &amp; Co. from $17.00 to $16.00 and set an &#34;equal weight&#34; rating for the company in a research report on Friday, February 14th. TD Cowen raised shares of Organon &amp; Co. to a &#34;hold&#34; rating in a research report on Wednesday, January 15th. Finally, Barclays decreased their target price on Organon &amp; Co. from $26.00 to $24.00 and set an &#34;overweight&#34; rating for the company in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and an average price target of $20.80.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該公司發佈了報告。摩根士丹利在 2 月 14 日的研究報告中將 Organon &amp; Co.的目標價從$17.00 下調至$16.00，並給予該公司 “持平” 評級。TD Cowen 在 1 月 15 日的研究報告中將 Organon &amp; Co.的股票評級上調至 “持有”。最後，巴克萊在 2 月 14 日的研究報告中將 Organon &amp; Co.的目標價從$26.00 下調至$24.00，並給予該公司 “增持” 評級。一位分析師對該股給予了賣出評級，三位分析師給予了持有評級，兩位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat.com 的數據，該股目前的平均評級為 “持有”，平均目標價為$20.80。</p>
</div><p><strong>Read Our Latest Stock Report on Organon &amp; Co.</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 Organon &amp; Co.股票報告</strong></p>
</div><h2>Organon &amp; Co. Trading Down 9.6 %</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 股價下跌 9.6%</h2>
</div><ul>
<li>Lululemon Athletica Races to New High with S&amp;P 500 Entry</li>
</ul>
<div class="lb-trans"><ul>
<li>Lululemon Athletica 因進入標準普爾 500 指數而創下新高</li>
</ul>
</div><p>The firm's 50-day simple moving average is $15.22 and its 200-day simple moving average is $16.10. The firm has a market capitalization of $3.37 billion, a PE ratio of 3.92, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為$15.22，200 日簡單移動平均線為$16.10。該公司的市值為 33.7 億美元，市盈率為 3.92，市盈增長比率為 0.90，貝塔值為 0.76。該公司的速動比率為 1.21，流動比率為 1.70，債務股本比率為 17.73。</p>
</div><p>Organon &amp; Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon &amp; Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Equities analysts expect that Organon &amp; Co. will post 3.68 earnings per share for the current year.</p>
<div class="lb-trans"><p>Organon &amp; Co. (NYSE:OGN - 獲取免費報告) 最近在 2 月 13 日發佈了季度財報。該公司報告每股收益（EPS）為$0.83，低於市場共識預期的$0.92，差額為 ($0.09)。Organon &amp; Co.的股本回報率為 431.62%，淨利潤率為 13.49%。該公司本季度的收入為 15.9 億美元，而市場共識預期為 15.7 億美元。股票分析師預計 Organon &amp; Co.在當前年度的每股收益將達到 3.68。</p>
</div><h2>Organon &amp; Co. Dividend Announcement</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 分紅公告</h2>
</div><p>The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 8.57%. Organon &amp; Co.'s payout ratio is currently 33.63%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度分紅，已於 3 月 13 日支付。2 月 24 日的登記投資者獲得了$0.28 的分紅。該分紅的除息日期為 2 月 24 日。這代表着年化分紅為$1.12，分紅收益率為 8.57%。Organon &amp; Co.的派息比率目前為 33.63%。</p>
</div><h2>Institutional Trading of Organon &amp; Co.</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 的機構交易</h2>
</div><p>Institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in Organon &amp; Co. in the third quarter worth about $113,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Organon &amp; Co. by 8.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 55,506 shares of the company's stock valued at $1,062,000 after purchasing an additional 4,298 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Organon &amp; Co. by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 836,389 shares of the company's stock valued at $16,000,000 after buying an additional 4,029 shares in the last quarter. Verition Fund Management LLC bought a new position in Organon &amp; Co. in the 3rd quarter worth $195,000. Finally, Paloma Partners Management Co bought a new position in shares of Organon &amp; Co. in the third quarter worth about $362,000. Hedge funds and other institutional investors own 77.43% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近對該股票的持倉進行了調整。Quantbot Technologies LP 在第三季度購買了 Organon &amp; Co.的新股份，價值約為$113,000。蘇黎世州立銀行在第三季度將其在 Organon &amp; Co.的持倉提高了 8.4%。蘇黎世州立銀行現在擁有該公司 55,506 股股票，價值$1,062,000，此前在該期間又購買了 4,298 股。瑞銀資產管理美國有限公司的一個獨立業務單位在第三季度將其在 Organon &amp; Co.的持倉提高了 0.5%。瑞銀資產管理美國有限公司的一個獨立業務單位現在擁有 836,389 股該公司的股票，價值$16,000,000，此前在上個季度又購買了 4,029 股。Verition Fund Management LLC 在第三季度購買了 Organon &amp; Co.的新股份，價值$195,000。最後，Paloma Partners Management Co 在第三季度購買了 Organon &amp; Co.的股份，價值約為$362,000。對沖基金和其他機構投資者持有該公司 77.43% 的股票。</p>
</div><h2>Organon &amp; Co. Company Profile</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Organon &amp; Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.</p>
<div class="lb-trans"><p>Organon &amp; Co.是一家基於科學的全球製藥公司，致力於通過一系列處方療法在女性健康、生物類似藥和成熟品牌領域開發和提供創新健康解決方案。該公司成立於 2020 年 3 月 11 日，總部位於新澤西州澤西市。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Organon &amp; Co.</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>Archer Aviation’s Africa Deal Could Boost ACHR Stock</li>
<li>What to Know About Investing in Penny Stocks</li>
<li>Are Short Sellers Wrong About These 3 Semiconductor Stocks?</li>
<li>Investing in Construction Stocks</li>
<li>Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Organon &amp; Co.更好</li>
<li>內部人士買入解釋：投資者需要知道的事項</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>投資便士股票需要知道的事項</li>
<li>空頭賣家對這三隻半導體股票是否錯誤？</li>
<li>投資建築股票</li>
<li>波音在 3 月份獲得 500 億美元訂單——BA 股票現在值得買嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Organon &amp; Co. Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Organon &amp; Co.嗎？</h2>
</div><p>Before you consider Organon &amp; Co., you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Organon &amp; Co.之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon &amp; Co. wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Organon &amp; Co.並不在名單上。</p>
</div><p>While Organon &amp; Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Organon &amp; Co.目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Organon & Co. (NYSE:OGN) 創下新的 12 個月低點 - 你應該賣出嗎？